© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Studies Give a Window Into the Evolving French Biosimilars Market
Kelly Davio
November 6 2019
France has experimented with financial incentives to reward the prescribing of biosimilars. These incentive structures include shared savings for centers that acquire medicines at lower costs, as well as biosimilar prescribing targets.
Perceptions and Policies Still Holding Back Biosimilars in Europe
Kelly Davio
November 5 2019
During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting being held in Copenhagen, Denmark, 3 teams of researchers presented findings that show that, despite the fact that Europe’s biosimilars market is far more mature than that of the United States, the region still sees setbacks from stakeholder perceptions of biosimilars and from policies that do not adequately incentivize biosimilar use.
Amgen's Anticancer Biosimilars Could Provide Substantial Hospital Budget Savings to Italian System
Kelly Davio
November 4 2019
The International Society for Pharmacoeconomics and Outcomes Research is holding its Europe 2019 meeting this week in Copenhagen, Denmark, and the savings that biosimilars can afford European healthcare systems are a hot topic at this year’s event. Two studies presented on Monday explored how Amgen’s biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti) could produce significant cost savings for hospitals in the Italian healthcare system.
Arrow Declarations Are an Emerging Feature in the Biosimilar Patent Landscape
Kelly Davio
September 27 2019
In the US context, legal issues surrounding patents are often cited as one of the main hurdles to biosimilars. Despite the fact that patents on innovator drugs are often fewer in Europe, the patent landscape in the European Union remains complex and continues to evolve. During the SMi 10th Annual Biosimilars Conference, Gregory Bacon, DPhil, GDipIPLaw, partner at Bristows LLP, gave attendees a closer look at one emerging feature of the EU patent landscape that is of particular concern to biosimilar developers: the Arrow declaration.
Biosimilar Developers Have the Chance to Innovate With Device Design, Novartis Leader Says
Kelly Davio
September 26 2019
Innovation is not always the first term that comes to mind with respect to biosimilars; after all, having no clinically relevant differences between products is at the heart of biosimilarity. However, as Sebastian Maag, device project leader for Novartis–Sandoz GmbH, told attendees during the second day of the SMi 10th Annual Biosimilars Conference, biosimilar developers have the opportunity to introduce innovations with the design of their devices for drug delivery.
IQVIA Analyst Looks at Current Developments and the Decade Ahead for Biosimilars
Kelly Davio
September 25 2019
The global biosimilars market is beginning to take on a more defined shape as blockbuster therapies lose their exclusivities, the United States sees the entrance of the first anticancer biosimilars, and Europe gains experience and savings with adalimumab biosimilars. But what will the coming decade hold in terms of new development projects and global sustainability?
Biogen Director Shares Lessons Learned From EU Biosimilar Commercialization
Kelly Davio
September 25 2019
During the opening day of the SMi 10th Annual Biosimilars Conference, held September 25-26 in London, United Kingdom, Dan Cohen, Biogen’s regional senior director of biosimilars for the United Kingdom, Ireland, and the Netherlands, shared his experience with anti–tumor necrosis factor biosimilars in general, and with biosimilar adalimumab in particular, in the EU marketplace.
Attorneys, Others Discuss Current Trends in Biosimilar Development
Allison Inserro
June 28 2019
ACI 11th Summit on Biosimilars & Innovator Biologics
Industry insiders discuss current trends about the patent dance and other issues, as well as proposed legislation that could affect biosimilar development.